Clovis Oncology Inc
Change company Symbol lookup
Select an option...
CLVS Clovis Oncology Inc
TANNI Travelcenters of America Inc
CONN Conn's Inc
F Ford Motor Co
SYF Synchrony Financial
ES Eversource Energy
LVGO Livongo Health Inc
SJMiv.P Invesco BulletShares 2022 Hi Yld Corp Bd ETF
INTC Intel Corp
AAPL Apple Inc
Go

Health Care : Biotechnology | Small Cap GrowthCompany profile

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product Rubraca (rucaparib), an oral small molecule inhibitor of poly adenosine diphosphate (ADP)-ribose polymerase (PARP), is marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The Company also provides Lucitanib, which is an investigational, oral, potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors one through three (VEGFR1-3), platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors one through three (FGFR1-3).

Closing Price
$10.71
Day's Change
1.10 (11.45%)
Bid
--
Ask
--
B/A Size
--
Day's High
10.87
Day's Low
9.70
Volume
(Light)
Volume:
14,076,771

10-day average volume:
22,065,488
14,076,771

Company Profile

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product Rubraca (rucaparib), an oral small molecule inhibitor of poly adenosine diphosphate (ADP)-ribose polymerase (PARP), is marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The Company also provides Lucitanib, which is an investigational, oral, potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors one through three (VEGFR1-3), platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors one through three (FGFR1-3).

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
3.93x
Price/Book (MRQ)
--
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

November 2019
Current Month
26.9M
Previous Month
22.0M
Percent of Float
50.85%
Days to Cover
2.1033 Days

Share Information

CLVS is in a share class of common stock
Float
53.1M
Shares Outstanding
54.8M
Institutions Holding Shares
200
100.59%

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in millions.

Company Officers

  • Ginger L. GrahamChmn.
  • Patrick J. MahaffyPres.
  • Gillian C. Ivers-Read
  • Daniel W. MuehlCFO
  • Paul E. GrossExec.VP

Address

Insider Trading

During the most recent quarter, 108K shares were bought, and 10K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Information provided by , Copyright © 2019. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.